BigHat Biosciences Announces $75 Million Series C Financing to Advance AI-Designed Therapeutics and Leading Agentic Data Platform for Rapid Protein Design
SAN MATEO, Calif.--(BUSINESS WIRE)--BigHat Biosciences, a clinical-stage, AI-driven protein therapeutics platform company, today announced the completion of a $75 million Series C financing, bringing its total funding raised to date to $223 million. The round was co-led by DFJ Growth & Premji Invest with participation from Catalio Capital Management, LG Technology Ventures, Sigmas Group, and existing investors including 8VC, Alexandria Venture Investments, Amgen Ventures, Andreessen Horowit